1. Invasive Multidrug-Resistant emm93.0 Streptococcus pyogenes Strain Harboring a Novel Genomic Island, Israel, 2017–2019
- Author
-
Merav Ron, Tal Brosh-Nissimov, Zinaida Korenman, Orit Treygerman, Orli Sagi, Lea Valinsky, and Assaf Rokney
- Subjects
Microbiology (medical) ,Adult ,Male ,Genomic Islands ,Epidemiology ,Streptococcus pyogenes ,Research ,Clindamycin ,Infectious and parasitic diseases ,RC109-216 ,Microbial Sensitivity Tests ,Anti-Bacterial Agents ,Infectious Diseases ,Streptococcal Infections ,Invasive Multidrug-Resistant emm93.0 Streptococcus pyogenes Strain Harboring a Novel Genomic Island, Israel, 2017–2019 ,Medicine ,Humans ,Israel ,Original Research - Abstract
Invasive group A Streptococcus (iGAS) infections have increased in Israel since 2016 as successful lineages have emerged. We report the emergence and outbreak of a multidrug-resistant S. pyogenes emm93.0, sequence type 10, among iGAS infections in Israel since 2017. This type has been observed very rarely in other countries. During this period, emm93.0 was the cause of 116 infections in Israel and became the leading type during 2018. Most of the infections were from bacteremia (75%), and most patients were male (76%). We observed infections across Israel, mainly in adults. Of note, we observed multidrug resistance for clindamycin, tetracycline, and trimethoprim/sulfamethoxazole. Whole-genome sequencing confirmed clonality among geographically disseminated isolates. The local emm93.0 sequence type 10 clone contained a novel genomic island harboring the resistance genes lsa(E), lnu(B), and ant (6)-Ia aph(3′)-III. Further phenotypic and genomic studies are required to determine the prevalence of this resistance element in other iGAS types.
- Published
- 2022